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Molecular analysis of meningioma increases prognostic power: A methylation-based classification 
and grading system 
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Summary  
Background 
The World Health Organization (WHO) classification of brain tumors describes 15 subtypes of 
meningioma. Nine of these are allotted to WHO grade I, and three each to grade II and grade III, 
respectively. Grading is purely based on histology, with molecular markers lacking. While the current 
classification and grading approach is of prognostic value, it harbors shortcomings such as ill-defined 
parameters for subtypes and grading criteria prone to arbitrary judgment.  
Methods 
We investigated genome-wide DNA methylation patterns of 479 meningiomas to identify distinct 
methylation classes (MC) of meningioma. The MCs were further characterized by DNA copy-number 
analysis, mutational profiling and RNA sequencing. We validated our findings in an independent 
cohort of 140 tumors. 
Findings 
DNA methylation profiling distinguished six distinct MCs associated with typical mutational, 
cytogenetic, and gene expression patterns. Meningioma MCs exhibit a more homogeneous clinical 
course and allow prognostication with significantly higher power than the current morphology-based 
WHO classification. Meningioma MCs more accurately identify patients at high risk of recurrence 
among tumors with WHO grade I histology, and patients at lower risk of recurrence among WHO 
grade II tumors. DNA methylation-based classification and grading reduces the number of 
meningioma subtypes from 15, as historically defined by histology, to six clinically relevant MCs, each 
with a characteristic molecular and/or clinical profile.  
Interpretation 
DNA methylation-based meningioma classification captures biologically more homogenous groups 
and has a higher power for predicting tumor recurrence than the current WHO classification. The 
approach presented here is highly useful for stratifying meningioma patients for observation or 
adjuvant treatment groups. We consider methylation-based tumor classification highly relevant for 
the future diagnosis and treatment of meningioma. 
Funding 
This work was supported by the German Cancer Aid (110670, 110983) and the Else Kröner-Fresenius 
Foundation (A_60). We thank the DKFZ-Heidelberg for funding by HIPO H033. 
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Research in context 
 
Evidence before this study 
Meningiomas, the most frequent primary intracranial tumors, are diagnosed and graded according to 
the WHO classification of brain tumors. The recent update of this classification in 2016 has 
implemented molecular markers for several brain tumor entities.  
However, there are still no established prognostic molecular markers for meningioma. Meningioma 
diagnostics is still based on purely histological criteria which are prone to a high inter-observer and 
sampling bias. Thus, the relevance of the current grading system for clinical decision making is 
heavily debated.  
 
Previous work by several groups, including ours, has shown that DNA methylation signatures are 
specific for tumor entities. Importantly, DNA methylation profiling can identify biologically and 
clinically relevant subgroups among histologically indiscernible cases. Here, we employed this 
concept for the classification of meningiomas. A search in PubMed on October 21 2016 did not 
identify articles which used high-resolution DNA methylation profiling for identification of clinically 
relevant subgroups across all subtypes and grades of meningioma.  
 
Added value of this study 
We demonstrate that classification of meningiomas based on DNA methylation profiling is more 
powerful in predicting the clinical behavior than the current WHO classification and grading system. 
Our findings on a discovery series were confirmed on an independent validation series. Most notably, 
the novel approach was capable of identifying patients at high risk of rapid recurrence which were 
expected to have benign tumors based on WHO grading. Likewise, a considerable fraction of patients 
with the histological diagnosis of a higher grade meningioma - fostering the consideration of 
adjuvant treatment - but no recurrence could upfront be identified as low risk by DNA methylation 
profiling.  
 
Implications of all the available evidence 
Our data demonstrate that meningioma patients can be more accurately stratified for tumor 
behavior by DNA methylation profiling than by the current WHO classification. This greatly improves 
the basis for clinical decision making for or against additional therapy after surgery. We expect 
epigenetic profiling to be included into the diagnostic routine and implemented into upcoming 
updates of the WHO classification for brain tumors. 
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Introduction 
The meninges exert a protective function for the entire central nervous system (CNS). During 
development, their precursor cells emerge from mesodermal structures and the neural crest, actively 
contributing to the differentiation of the brain1-3. However, meningeal cells may transform to initiate 
tumors. These meningiomas are the most frequent primary intra-cranial and spinal tumors 4. While 
80 % of meningiomas show a benign clinical behavior and can be cured by resection alone, about 20 
% recur and need additional treatment such as repeated surgery, irradiation, and systemic 
chemotherapy4,5. Histopathological evaluation aims at the identification of cases at risk for 
recurrence. The histological differentiation into subtypes initially dates back to the 19th century. 
Later, in a first internationally recognized classification approach in 1928, Bailey and Cushing 
distinguished meningothelial, fibroblastic, and angiomatous subtypes 6, and to this day, allocation to 
subtype is based solely on histological findings. The current WHO classification recognizes 15 
subtypes and three grades of malignancy4, but some of the diagnostic criteria are vaguely defined 
and subject to a high inter-observer bias, indicating the need for more reliable markers5,7.  
For various other CNS tumors, molecular profiling has identified distinct subtypes with characteristic 
aberrations. Many of these correlate with prognosis or provide targets for treatment, and therefore 
support clinical decision making, e.g. epigenetic subgroups in medulloblastoma8-10 and 
ependymoma11, or isocitrate dehydrogenase (IDH) status in diffuse glioma12-14. Recent studies 
identified telomerase reverse transcriptase (TERT) promoter mutations in a small subset of 
meningiomas to be associated with higher risk of recurrence and shorter time to progression15,16, and 
four large exome-sequencing efforts focusing on WHO grade I meningiomas have identified 
recurrently mutated genes beyond the long-known association with NF2 17-20. Yet, these findings 
cover only a fraction of meningiomas and have not all been thoroughly tested for their prognostic 
relevance. In this study, we aimed at a comprehensive characterization of the entire molecular 
genetic landscape of meningioma in order to identify biologically and clinically relevant subgroups 
that refine the current classification scheme. 
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Results 
 
DNA methylation analysis identifies six distinct methylation classes of meningioma 
We generated genome-wide DNA methylation profiles from a discovery cohort of 497 meningiomas 
(Suppl. Fig. 1) along with 309 samples of other extra-axial skull tumors that may histologically mimic 
meningioma variants, including solitary fibrous tumor/hemangiopericytoma, schwannoma, malignant 
peripheral nerve sheath tumors, chordoma, chondrosarcoma, fibrous dysplasia, and 
hemangioblastoma. Despite sharing a mesodermal origin, unsupervised clustering of DNA 
methylation data clearly segregated all meningiomas from other skull tumors (Suppl. Fig 2). 
Unsupervised clustering of meningiomas alone revealed two major epigenetic groups (Groups A and 
B, Fig. 1A), with both groups further subdividing into four and two subgroups, respectively. These six 
subgroups were designated as “methylation classes” (MCs). Based on further molecular and clinical 
characteristics outlined below, the four MCs of Group A were designated MC benign 1 through 3 (MC 
ben-1, ben-2, ben-3) and MC intermediate A (MC int-A). The two MCs of Group B were designated 
MC intermediate B (MC int-B), and malignant (MC mal). 
There was an enrichment of grade I tumors among MC ben-1, MC ben-2, and MC ben-3, and an 
enrichment of WHO grade III tumors in MC mal, while WHO grade II tumors where scattered across 
all MCs. Analysis of 75 primary and matched recurrent tumors from 37 patients showed that 
association with Group A or B was stable upon recurrence (Fig. 1B), supporting further assessment of 
methylation profiling for diagnostic and prognostic implications. 
 
MC predict clinical course with higher accuracy than WHO grading 
The wide spectrum of clinical behavior among WHO grade I and II meningiomas points towards the 
limited prognostic power of the current classification, particularly at the border between grade I and 
II. As a result, the basing of decisions about radiotherapy on the current grading scheme is heavily 
debated 5. Thus, we correlated meningioma MCs with progression-free survival (PFS) to evaluate 
their potential for predicting outcome compared to WHO grading (Fig. 2A, B). We further combined 
MCs exhibiting virtually identical benign (MC ben-1, MC ben-2, MC ben-3) or intermediate (MC int-A, 
MC int-B) outcome into combined MCs (Fig. 2C). Classification by individual and combined MCs 
demonstrates more precise prognostication than by WHO grading (Fig. 2D, Brier prediction test, 
p <0·01). These findings were confirmed in 140 meningiomas from an independent validation cohort 
(Suppl. Fig 3A, B).  
We next focused on the prediction power of MCs within WHO grades and, particularly, patients 
divergently diagnosed by WHO grading and DNA methylation-based classification. Patients with WHO 
grade I meningiomas who were molecularly assigned to an intermediate MC experienced a less 
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favorable clinical course than patients with WHO grade I meningiomas diagnosed solely based on 
histology. In fact, their outcome was indistinguishable from that of patients with WHO grade II 
meningiomas (Fig. 3A). Likewise, patients with WHO grade II meningiomas molecularly assigned to a 
benign MC had a better outcome than the average outcome of patients with histologically-defined 
WHO grade II meningiomas. Consequently, stratification for MC is of higher value for prediction of 
PFS than WHO grading. Within the combined MCs, WHO grading confers limited additional 
information (Fig. 3B, Suppl. Table 2). However, combined MCs delineate subgroups with significantly 
distinct prognosis within all WHO grades (Fig. 3C), demonstrating the benefit of MC-based grading for 
patients and the potential to significantly reduce under- or overtreatment. 
 
Methylation classes are associated with distinct driver mutations and copy-number-alterations 
We next sequenced 304 meningiomas with sufficient material available using a custom hybrid-
capture next-generation sequencing (NGS) panel dedicated to 40 genes previously reported to be 
mutant in meningioma (Suppl. Table 1), based on our recently established custom NGS approach for 
routine brain tumor diagnostics21. Known recurrent mutations (most frequently NF2, followed by 
TRAF7 and AKT1) were significantly enriched in certain MCs (Suppl. Table 3, Fig. 4). Within Group A, 
NF2 mutations were observed in 63 % of MC ben-1 tumors (significant accumulation of parameter in 
this MC, p <0·0001, Fisher’s exact test). MC ben-2 contained the vast majority of meningiomas 
carrying AKT1 (33 % in this subgroup; p < 0·0001), SMO (7 %; p =0·0002), KLF4 (15 %; p < 0·0001), and 
TRAF7 (49 %; p < 0·0001) mutations, but only rarely harbored NF2 mutations. Only one AKT1 and five 
KLF4 mutations were detected outside of MC ben-2. MC ben-3 exhibited NF2 mutations in 32 % and 
PIK3CA mutations in 11 % of tumors, representing the majority (5/7, 71 %) of PIK3CA mutations in 
the cohort. MC int-A carried NF2 mutations in 53 %. Within Group B, MC int-B tumors harbored NF2 
mutations in 35 % and MC mal in 31 % of cases. SUFU mutations were confined to Group B, with 5 % 
of MC int-B and 6 % MC mal tumors being mutated. Four out of five TERT promoter mutations 
mapped to meningiomas in Group B (p = 0·005, Fisher’s exact test).  
Annotation of copy-number-variations (CNV) revealed that MCs are associated with distinct 
cytogenetic aberrations (Fig. 4A, B): MC ben-1 was associated with deletions of 22q (95 %) but 
otherwise virtually no CNV. MC ben-2 presented with absence of recurrent CNVs. Typical for MC ben-
3 were multiple chromosomal gains, most frequently affecting chromosome 5 (47 %). MC int-A 
frequently exhibited losses on 1p (70 %) and 22q (84 %). In Group B, MC int-B frequently exhibited 
losses on 1p (89 %), 10 and 22 (89 %), all features also shared with MC malignant. However, in MC 
mal, a higher frequency of CDKN2A deletion was apparent (70%).  
Representative cases with sufficient material available of all MCs underwent RNA-sequencing which 
identified differentially upregulated genes and pathways (Suppl. Fig. 4).  
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Methylation classes and WHO subtypes, localization, and gender 
Examining the distribution of histological subtypes, which currently determine grading, across MCs 
revealed which histological subtypes the MCs are composed of and, conversely, to which MC the 
samples of a respective subtype are assigned (Fig. 5). The rare lymphoplasmacyte-rich meningioma 
(WHO grade I) was not assessed due to the overwhelming dominance of constitutional (non-tumor) 
DNA in these samples. In general, two patterns were observed: Either a given MC was strongly 
associated with a small set of or even single histological subtypes, or samples of a particular MC or 
subtype were widely spread across all corresponding variants. MC ben-1 comprised the majority of 
fibroblastic meningiomas and is also enriched for psammomatous meningioma. Fibroblastic 
meningiomas frequently harbor calcifications called psammoma bodies, and a high abundance of 
these calcifications defines psammomatous meningioma. Their molecular similarity implies that they 
may rather represent a continuous spectrum of one phenotypic pattern. The overexpression of 
SERPINF1 (Suppl. Fig. 4), which has been implicated in osteogenesis and calcification, in MC ben-1 
might contribute to this histologically detected phenomenon. MC ben-2 was highly enriched for 
meningothelial meningiomas, and contained the vast majority of secretory meningioma. MC ben-3 
harbored cases from several subtypes but was particularly enriched for angiomatous meningiomas. 
This is in line with the overexpression of vessel-associated markers, e.g. factor VIII, in samples of this 
MC (Suppl. Fig. 4). Transitional meningioma, a hybrid of meningothelial and fibroblastic histology, 
dissolved into several MCs, along with the samples of the rare microcystic, chordoid, metaplastic, 
psammomatous, and clear cell subtype.  
The two intermediate MCs were predominantly constituted of atypical meningiomas. However, a 
considerable fraction of atypical meningioma (n=31) fell into MC ben-1. The improved resolution of 
this group substantially contributes to the higher prognostic power of MC class over histology. 
Anaplastic meningiomas predominantly mapped to MC malignant. Of note, the six rhabdoid/papillary 
meningiomas, by definition WHO grade III, all ended up in one of the MC benign or intermediate 
meningioma groups. However, the number was too low to assess the statistical relevance of WHO 
grading and MC classification individually for rhabdoid/papillary meningioma. 
Transitional meningioma WHO grade I was much more frequently assigned to an intermediate MC 
than fibroblastic or meningothelial meningioma, mostly to MC int-A. Atypical meningiomas assigned 
to a benign MC accumulated in MC ben-1.  
The most frequent localizations for all subgroups were the frontal and central convexity, except for 
MC ben-2 (Fig 6). For the latter, basal localization was common, in line with the high occurrence of 
AKT1 and SMO mutations in this MC which are known to be enriched in this location 19,22. 
Interestingly, all MC mal cases were located at the convexity. In contrast, none of the basal tumors 
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were allotted to MC mal, including four intraventricular and ten spinal meningiomas that were all 
assigned to intermediate or benign MCs. Age distribution was equal throughout all MCs. In terms of 
gender, we observed a predominance of male patients in MC mal, while all other MCs mainly 
comprised female patients (Fig 6).  
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Discussion 
The 15 subtypes of meningioma included in the current WHO classification have evolved over 
decades. The major aim of introducing this variety of subgroups was to cover the whole histological 
spectrum of meningioma and to avoid misclassification of tumors mimicking other entities. For 
example, meningeal tumors with chordoid or rhabdoid cytology may initially raise suspicion of a 
chordoma or rhabdoid tumor but not point towards meningioma. Therefore, particular subtypes with 
these features were introduced into the classification in order to draw attention to the morphologic 
diversity of meningioma. In addition, some cytological features have been reported to be associated 
with distinct outcome. Although this was based on small series, it prompted allotment of distinct 
WHO grades to specific meningioma subtypes. However, this approach has been increasingly 
questioned due to suboptimal inter-observer reproducibility and limited prognostic effect of the 
histological criteria of higher grade 7,23,24, most recently in a large Radiation Therapy Oncology Group 
(RTOG) meningioma trial 7 in which the authors expressed the urgent need for more objective, 
molecular stratification markers.  
This resulted in an overall critical view of clinicians with respect to the current meningioma WHO 
classification and grading, which has been expressed in the most recent published European 
Association of Neuro-oncology (EANO) guideline for the diagnosis and treatment of meningiomas5. 
Accordingly, revisiting meningioma diagnostics based on DNA methylation profiling by defining MCs 
with enhanced predictive power will greatly improve the acceptance of meningioma classification 
and more successfully guide decisions regarding postoperative treatment. An overview on the 
molecular and clinical hallmarks of the six meningioma MCs is given in Figure 6.  
 
Distinct methylation profiles suggest different development 
Beyond the identification of clinically relevant groups and the basis for a novel classification, our 
dataset might provide insight into the development of meningioma. This has previously been shown 
for other entities: Four variants of medulloblastoma, distinguishable by their DNA methylation 
patterns, were shown to arise from different precursor cell populations8,25-27, and exhibit very 
different clinical characteristics and therapy needs. Our data indicate that the spectrum of 
meningiomas is divided into two major molecularly highly distinct Groups (A and B, Fig. 1). This 
strong separation suggests either the existence of distinct cells of origin or an underlying event with 
major impact on genome-wide DNA methylation. The very different DNA methylation profiles of 
Groups A and B despite the shared occurrence of NF2 mutations might suggest that meningiomas 
arise from two different precursor cell populations. Based on our own and published high-
throughput sequencing data, there is no evidence for the existence of a single mutation being solely 
responsible for the separation of these two groups. However, we cannot fully exclude the existence 
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of alterations not readily detectable by these approaches, such as translocations or fusions, causing 
the responsible changes in the methylome. Moreover, the fact that patients with meningiomas 
clustering in Group A share a predominantly benign, with a small proportion exhibiting a 
intermediate clinical course, and that patients with meningiomas of Group B follow an intermediate 
to malignant clinical course, may further argue towards a distinct cell of origin with different intrinsic 
propensities for malignant transformation. However, analyses dissecting the full regulatory 
background of the tumor cells in comparison to arachnoidal cells, e.g. by H3K27Ac ChIP-Sequencing, 
are needed to further elucidate this.  
 
 
Methylation-based versus WHO subgrouping versus other molecular markers 
Extensive whole exome or -genome sequencing has provided a large body of information on the 
mutational landscape of meningioma17-20. Four distinct meningioma mutational subgroups have been 
proposed, defined by mutations either in NF2, TRAF7, the hedgehog pathway, or POLR2A18. However, 
such a model of meningioma development based on mutational analysis alone currently does not 
satisfy the clinical need for distinction between patients in need of adjuvant treatment or not. A 
major drawback is the lack of risk stratification among NF2-mutant cases, which can present with any 
clinical course. While the strong association of AKT1, TRAF7/KLF4, or SMO mutations with benign, or 
TERT promoter mutations with unfavorable course may allow for mutation-based risk assessment in 
these subgroups, the current inability to stratify NF2-mutated meningiomas for other mutational 
events associated with clinical outcome is a major obstacle for a classification and grading system 
based on mutational profiling alone. 
Similarly strong limitations apply to approaches based on copy-number-profiles: They leverage the 
accumulation of aberrations during progression but are not capable of predicting the behavior 
upfront. The current dataset attributes the highest prognostic power to methylome-based 
subgrouping, which proves to be superior to WHO classification (Fig. 2, 3), while an exclusively 
mutation-based subgrouping for the full spectrum of meningioma is not available. 
 
An integrated diagnosis for meningioma evaluation 
The WHO 2016 revision of the classification for CNS tumors supports the concept of an integrated 
diagnosis. It relies on a multilayered approach combining data from histology, molecular genetic 
analyses, and clinical findings4,28,29. Adopting this WHO approach to the diagnosis of meningioma, the 
morphological layer corresponds to the current diagnostic standard, i.e. diagnosing the 15 WHO 
meningioma subtypes and grading according to the morphological scheme. In the absence of 
molecular analyses the morphological diagnosis should be suffixed with NOS (not otherwise 
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specified), as agreed for parenchymal brain tumors without molecular workup4. The molecular 
diagnostic layer may contain elements such as DNA methylation and/or mutation analyses. 
Mutational data may enable inferring the MC for a subset within the MC ben-2, e.g. for AKT1 mutant 
cases, but not in every instance. With methylation analysis performed, one of the six MCs can be 
diagnosed. If the MC is identified, this results in a significantly more powerful prediction of the 
clinical course. This corresponds to the current approach in other entities, e.g. ependymoma and 
medulloblastoma, for which methylation profiling has proven to be more relevant than histological 
grading4,11. Based on the data presented here, the integrated diagnosis of meningioma will also 
highlight the prognostic impact of MCs, but in addition refer to the morphological subtype identified 
in histological examination.  
Collectively, the dataset and accompanying classification scheme proposed here advances 
meningioma diagnostics from histology into an integrated profiling with higher accuracy of risk 
assessment for individual patients.  
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Materials and Methods 
Samples 
Samples with clinical data were retrospectively collected from the Dept. of Neuropathology 
Heidelberg, Germany (local and referral cases), Dept. of Neurosurgery Heidelberg and the FORAMEN 
network, the Dept. of Neurology and Neuropathology, Zürich, Switzerland, and the Neurological 
Institute (Edinger Institute) Frankfurt/Main, Germany. Additional samples without survival 
annotation were included from the Dept. of Neuropathology and Neurosurgery Berlin, Bonn, 
Hamburg, Magdeburg, Münster, Tübingen (all Germany), and Bristol (UK). The validation cohort was 
provided by the Medical University of Vienna. Sample and data collection was in accordance with 
local ethical regulations. 
 
Methylation analysis, copy-number analysis 
Unsupervised clustering of the 450k data of the discovery and the EPIC 850k data of the validation 
cohort was performed as previously described (see Supplementary Materials and Methods for 
references) based on Euclidian distance and Ward’s linkage method. For the clustering probes with a 
standard deviation greater 0.2 across all samples were selected. The methylation probes were 
reordered by hierarchical clustering using Euclidean distance and complete linkage.  
Copy-number aberrations were inferred from methylation array data using the R/Bioconductor 
package conumee. 
 
Cohort-wide copy number analysis in MCs 
Methylation-class wide relative copy-number assessment was performed based on 450k data by a 
proprietary algorithm and controlled by manual inspection of the conumee-based copy-number-
profiles (Stichel et al., in preparation). 
 
Panel and RNA sequencing 
Panel sequencing for genes reported to be mutant in meningioma (Suppl. Table 1) was performed 
applying a custom hybrid-capture approach (Agilent) as described before. RNA libraries were 
generated with TruSeq RNA Access (Illumina) applying manufacturer supplied protocols. Sequencing 
was performed on a NextSeq 500 (Illumina).  
 
Statistical analysis of clinical parameters 
Distribution of survival times was estimated by the method of Kaplan and Meier and compared 
between groups with the log-rank test. Hazard ratios including 95% confidence intervals based on 
Cox regression models were calculated. For the multivariable Cox regression model, imputations of 
missing covariate values was done applying the multivariate imputations using chained equations 
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(mice) algorithm with 100 imputation runs. Hazard ratio for age is given per 10 year increment. 
Prediction error curves based on the Brier score were computed. Integrated Brier score was tested 
between risk stratifications using 1000 bootstrap samples. P-values below 0.05 were considered 
statistically significant. Analyses were performed with statistical software R 3.3. 
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Legends 
 
Figure 1 Unsupervised clustering of methylation data of 479 meningioma samples (A). Unsupervised 
clustering of matched primary and recurrent samples (matched primary/recurrent samples of 
identical patient identified by arrows) combined with reference samples from group A and B shows 
that no shift between groups occurs upon recurrence (B). 
 
 
Figure 2 Progression free survival (PFS) of 228 case with clinical data stratified for WHO grade (A), 
methylation class (B), combined methylation classes (C). Brier prediction plot calculated for the 
models A-C (D, WHO vs combined MCs p=0·0138, 0·0096, 0·0062 for 5, 10 and 12 years, 
respectively). 
 
Figure 3 Comparison of WHO grading and methylation-based risk prediction: WHO grade I cases 
allotted to an intermediate methylation class show PFS similar to the average grade II tumors. In 
turn, WHO grade II cases assigned to a benign methylation class have longer PFS than the average 
WHO grade II cases (A). Hazard ratio (including 95% confidence intervals) forest plot for WHO 
grading, overall and stratified for combined methylation classes (B). Hazard ratio forest plot for 
combined methylation classes, overall and stratified for WHO grading (C). While sub-stratification for 
WHO grade among MCs is of limited additional value (B), MCs stratify for distinct PFS within WHO 
grades (C).  
 
Figure 4 Distribution of mutations across sample that underwent panel-sequencing (304) stratified 
for MCs (A). Copy number variations across all samples that underwent 450k analysis (497) the MCs 
(B). 
 
Figure 5 Association of histological subtypes and MCs. 
 
Figure 6 Schematic overview over the six identified MCs and their molecular and clinical 
characteristics  
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Supplementary Materials (online) 
Supplementary Figure 1: Composition of Discovery Cohort (WHO grade, subtype, age, localization, 
gender)  
Supplementary Figure 2: Unsupervised clustering of 450k methylation data of mesenchymal skull 
tumors and meningioma 
Supplementary Figure 3: Kaplan-Meier analysis for Validation cohort stratified for WHO grade (A) and 
Methylation Class (B) 
Supplementary Figure 4: Expression analysis based on RNA-sequencing data. Most differentially 
expressed genes in the six MCs (A) and ClueGo based on KEGG source data all samples (B). Nodes 
represent enriched gene sets, which are grouped and annotated by their similarity. Size is 
proportional to the number of involved genes. Manual curation was performed to remove 
uninformative sub-networks. 
Supplementary Materials and Methods: Detailed methods with references 
Supplementary Table 1: Multi-variate analyses 
 Supplementary Table 2: Genes included in panel sequencing 
Supplementary Table 3: Distribution of mutations in Methylation classes   
Supplementary Table 4: Clinical and mutational data of all cases 
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